A method of implementing organic synthesis reactions uses a composition containing a metal catalyst originating from a calcined plant. The plants can be from the Brassicaceae, Sapotaceae and Convolvulaceae family, and the metal catalyst contains metal in the M(II) form such as zinc, nickel, manganese, lead, cadmium, calcium, magnesium or copper. Examples of the organic synthesis reactions include halogenations, electrophilic reactions, cycloadditions, transesterification reactions and coupling reactions, among others.

This disclosure relates to a polymer that includes a first repeat unit and at least one end-cap group at one end of the polymer. The first repeat unit includes at least one imide moiety and at least one indane-containing moiety. The end-cap group is capable of undergoing a cycloreversion reaction. This disclosure also relates to a thermosetting composition containing the above polymer.

This disclosure relates to a polymer that includes a first repeat unit and at least one end-cap group at one end of the polymer. The first repeat unit includes at least one imide moiety and at least one indane-containing moiety. The end-cap group is capable of undergoing a cycloreversion reaction. This disclosure also relates to a thermosetting composition containing the above polymer.

The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and kits for predicting a patient's treatment outcome after administration of a microdose of therapeutic composition to the patient or a sample from the patient. The methods provides physicians with a diagnostic tool to segregate cancer patients into differential populations that have a higher or lower chance of responding to a particular therapeutic treatment.

The invention relates to a novel crystallization process for preparing fluticasone propionate as crystalline form 1 polymorph with controlled particle size and suitable for micronization. Said process comprises the step of dissolving fluticasone propionate in acetone or in a mixture of acetone and water and then adding this solution to water or to a mixture of water 10 and acetone, thereby causing fluticasone propionate to crystallize out of the solution as crystalline form.

Provided herein is a process and intermediates for the preparation of a compound of formula (I): ##STR00001##
or a pharmaceutically acceptable salt thereof, using cyanamide in the reaction.

Provided are a method for preparing a mammalian ovum or embryo in which zona pellucida has been thinned or eliminated, and a method for fertilization using the mammalian ovum prepared by the aforementioned method. The resulting mammalian ovum or embryo is capable of realizing an improved fertilization rate and development rate when used for in vitro fertilization, transplantation of a fertilized ovum, or for preparation of an embryo in the early stages of development used in the production of a genetically modified animal.

The present application discloses an efficient process for the preparation of N-acetyl-L-cysteine amide (NACA) starting with N-acetyl-L-cysteine.

The present application discloses an efficient process for the preparation of N-acetyl-L-cysteine amide (NACA) starting with N-acetyl-L-cysteine.

The present application discloses an efficient process for the preparation of N-acetyl-L-cysteine amide (NACA) starting with N-acetyl-L-cysteine.